{"transactions":[{"id":832395,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-20T20:05:07.000Z","date":"2026-03-19","kind":"grant","planned":false,"acquired":true,"shares":222000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on March 19, 2026. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 19, 2027, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":222000,"derivative":{"exercise_price":6.81,"expiration_date":"2036-03-18","underlying":"Common Stock","underlying_shares":222000},"source":{"system":"sec-edgar","filing":"0001193125-26-117618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000119312526117618/ownership.xml","form_type":"4"}},{"id":1173316,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-11T20:55:49.000Z","date":"2025-04-10","kind":"grant","planned":false,"acquired":true,"shares":287000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service."}],"balance_after":287000,"derivative":{"exercise_price":7.31,"expiration_date":"2035-04-09","underlying":"Common Stock","underlying_shares":287000},"source":{"system":"sec-edgar","filing":"0000950170-25-053347","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025053347/ownership.xml","form_type":"4"}},{"id":1200001,"issuer":{"id":6805,"kind":"organization","name":"Kalaris Therapeutics, Inc."},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-18T21:41:07.000Z","date":"2025-03-18","kind":"grant","planned":false,"acquired":true,"shares":476611,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Stock option assumed in connection with the closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of November 7, 2024 (the \"Merger Agreement\"), by and among the Issuer, Aurora Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Issuer, and Kalaris Tx, Inc. (previously named Kalaris Therapeutics, Inc.), a Delaware corporation (\"KTx\"), in exchange for an outstanding option to purchase shares of KTx pursuant to the terms and conditions of the Merger Agreement (such transaction, the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, as of the effective time of the Merger, each outstanding option to purchase shares of KTx common stock, whether or not vested, was converted into an option to acquire shares of common stock of the Issuer, with necessary adjustments to the number of shares and exercise price to reflect an exchange ratio equal to 0.2016 per share, on the same terms and conditions as were applicable immediately prior to the effective time of the Merger."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests over four years beginning on the vesting commencement date of March 4, 2024, with 25% of the shares underlying the option having vested on March 4, 2025, and an additional 1/48th the shares underlying the option vesting at the end of each successive one-month period thereafter."}],"balance_after":476611,"derivative":{"exercise_price":0.85,"expiration_date":"2034-05-27","underlying":"Common Stock","underlying_shares":476611},"source":{"system":"sec-edgar","filing":"0000950170-25-041485","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754068/000095017025041485/ownership.xml","form_type":"4"}},{"id":1809828,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2023-08-11T16:11:17.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"When granted, each restricted stock unit (\"RSU\") represented a contingent right to receive one share of the Issuer's Common Stock upon settlement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 28, 2024.  Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 28, 2024.  Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"When granted, the RSU award provided for ratable vesting in annual installments of one-third beginning on February 28, 2024.  Pursuant to the Merger Agreement (defined in the Remarks below), at the effective time of the Merger, the RSU award was cancelled and converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such RSU, (i) a cash payment equal to $40.00 (without interest and subject to any applicable tax withholding), and (ii) one CVR."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-045429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045429/doc4.xml","form_type":"4"}},{"id":1809827,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T16:11:17.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":160000,"price":18.18,"value":2908800.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option award, which provided for 25% of the award to vest on February 28, 2024 and ratable vesting in 36 additional monthly installments thereafter, became fully vested and was canceled upon effectiveness of the Merger (defined in the Remarks below), and was converted into the right to receive, with respect to each share of the Issuer's Common Stock underlying such option, (i) a cash payment representing the excess, if any, of the per share merger consideration ($40.00 per share) over the per share exercise price for such option, without interest, and (ii) one contingent value right (\"CVR\"), entitling the reporting person to additional cash payments upon the achievement of certain future business milestones pursuant to the contingent value rights agreement entered into concurrent with the completion of the Merger, in each case subject to applicable withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":21.82,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-23-045429","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123045429/doc4.xml","form_type":"4"}},{"id":1979264,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted Stock (RSU)(Common Stock)","published_at":"2023-03-02T17:00:38.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 28, 2024, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 28, 2024, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-23-014787","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123014787/doc4.xml","form_type":"4"}},{"id":1979263,"issuer":{"id":110632,"kind":"organization","name":"CHINOOK THERAPEUTICS, INC.","symbol":"KDNY"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-02T17:00:38.000Z","date":"2023-02-28","kind":"grant","acquired":true,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 25% of the total shares on February 28, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":160000,"derivative":{"exercise_price":21.82,"expiration_date":"2033-02-27","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001209191-23-014787","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1435049/000120919123014787/doc4.xml","form_type":"4"}},{"id":3006793,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-14T16:15:36.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":67500,"price":10.69,"value":721575.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."}],"balance_after":0,"derivative":{"exercise_price":23.81,"underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0000899243-20-028183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028183/doc4.xml","form_type":"4"}},{"id":3006792,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-10-14T16:15:36.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":150000,"price":12.56,"value":1884000.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each stock option outstanding and unexercised immediately prior to the Effective Time vested in full, terminated and was converted into the right to receive a cash payment equal to the product of (i) the number of shares of common stock that were subject to such stock option immediately prior to the Effective Time and (ii) the excess, if any, of the Offer Price over the per share exercise price of such stock option."}],"balance_after":0,"derivative":{"exercise_price":21.94,"underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-20-028183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028183/doc4.xml","form_type":"4"}},{"id":3006791,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-10-14T16:15:36.000Z","date":"2020-10-13","kind":"disposition_to_issuer","acquired":false,"shares":20250,"price":34.5,"value":698625.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Disposed of to SPN MergerSub, Inc. (\"Merger Sub\"), which, pursuant to the Agreement and Plan of Merger, dated August 29, 2020, by and between the Issuer, Societes des Produits Nestle S.A., (\"Nestle\"), and Merger Sub (the \"Merger Agreement\"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock (other than those shares owned by Nestle and its affiliates) at a purchase price of $34.50 per share (the \"Offer Price\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Merger Agreement, each Issuer restricted stock unit (\"RSU\") that was outstanding immediately prior to the date and time at which the Merger became effective (the \"Effective Time\") vested in full, terminated, and was converted into the right to receive a cash payment equal to (i) the Offer Price multiplied by (ii) the number of shares of common stock subject to the RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-028183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028183/doc4.xml","form_type":"4"}},{"id":3006790,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-10-14T16:15:36.000Z","date":"2020-10-10","kind":"other","acquired":false,"shares":6345,"price":34.5,"value":218902.5,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-028183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320028183/doc4.xml","form_type":"4"}},{"id":3029743,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-09-16T17:19:18.000Z","date":"2020-09-15","kind":"tax_withholding","acquired":false,"shares":840,"price":34.25,"value":28770.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,250 restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 9,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":26595,"source":{"system":"sec-edgar","filing":"0000899243-20-025349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320025349/doc4.xml","form_type":"4"}},{"id":3152138,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-05-12T17:20:19.000Z","date":"2020-05-10","kind":"grant","acquired":true,"shares":2420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the \"Vesting Date\"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest as to 100% of the underlying shares on September 11, 2020 (the \"Vesting Date\"), subject to the Reporting Person's continued service relationship with the Issuer on the Vesting Date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,250 RSUs and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 9,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":27435,"source":{"system":"sec-edgar","filing":"0000899243-20-012853","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320012853/doc4.xml","form_type":"4"}},{"id":3204130,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-03-17T16:51:30.000Z","date":"2020-03-13","kind":"purchase","acquired":true,"shares":3000,"price":14.7553,"value":44265.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average purchase price for the entire number of shares purchased. The actual purchase prices range from $14.5450 to $14.8500 per share. Information on the exact number of shares purchased at each purchase price can be obtained from the Issuer upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 11,250 restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 9,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":25015,"source":{"system":"sec-edgar","filing":"0000899243-20-008621","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320008621/doc4.xml","form_type":"4"}},{"id":3226308,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-04T21:53:05.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":67500,"derivative":{"exercise_price":23.81,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0000899243-20-007111","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320007111/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-03"}},{"id":3226307,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-03-04T21:53:05.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":22015,"source":{"system":"sec-edgar","filing":"0000899243-20-007111","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320007111/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-03"}},{"id":3226306,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-03-04T21:49:25.000Z","date":"2020-01-22","kind":"tax_withholding","acquired":false,"shares":1235,"price":33.23,"value":41039.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported sale was made pursuant to a pre-determined election to sell shares to cover tax withholding obligations in connection with the vesting of a previously reported equity award."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 9,000 restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":10765,"source":{"system":"sec-edgar","filing":"0000899243-20-007110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320007110/doc4.xml","form_type":"4"}},{"id":3230587,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-03T20:35:07.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":67500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":67500,"derivative":{"exercise_price":23.81,"expiration_date":"2030-02-28","underlying":"Common Stock","underlying_shares":67500},"source":{"system":"sec-edgar","filing":"0000899243-20-006850","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320006850/doc4.xml","form_type":"4"}},{"id":3230586,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2020-03-03T20:35:07.000Z","date":"2020-02-28","kind":"grant","acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 12,000 RSUs and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":23250,"source":{"system":"sec-edgar","filing":"0000899243-20-006850","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924320006850/doc4.xml","form_type":"4"}},{"id":3687717,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-01-24T16:06:22.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on January 22, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":150000,"derivative":{"exercise_price":21.94,"expiration_date":"2029-01-22","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0000899243-19-001869","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924319001869/doc4.xml","form_type":"4"}},{"id":3687716,"issuer":{"id":145931,"kind":"organization","name":"Aimmune Therapeutics, Inc.","symbol":"AIMT"},"owners":[{"id":56840,"kind":"person","name":"Oxtoby Andrew","position":1,"cik":"0001765473","reported_name":"Oxtoby Andrew","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common Stock, $0.0001 par value","published_at":"2019-01-24T16:06:22.000Z","date":"2019-01-22","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units (\"RSUs\") and will be settled in common stock upon vesting.  The RSUs vest in four successive, equal, annual installments measured from January 22, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date."}],"balance_after":12000,"source":{"system":"sec-edgar","filing":"0000899243-19-001869","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1631650/000089924319001869/doc4.xml","form_type":"4"}}]}